Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
WST 
West Pharmaceutical Services Inc (WST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: WST (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $278.84
1 Year Target Price $278.84
| 10 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.01% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.72B USD | Price to earnings Ratio 34.36 | 1Y Target Price 278.84 |
Price to earnings Ratio 34.36 | 1Y Target Price 278.84 | ||
Volume (30-day avg) 13 | Beta 1.09 | 52 Weeks Range 187.25 - 351.53 | Updated Date 06/30/2025 |
52 Weeks Range 187.25 - 351.53 | Updated Date 06/30/2025 | ||
Dividends yield (FY) 0.38% | Basic EPS (TTM) 6.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.13% | Operating Margin (TTM) 18.44% |
Management Effectiveness
Return on Assets (TTM) 10.33% | Return on Equity (TTM) 17.42% |
Valuation
Trailing PE 34.36 | Forward PE 35.97 | Enterprise Value 15623794818 | Price to Sales(TTM) 5.43 |
Enterprise Value 15623794818 | Price to Sales(TTM) 5.43 | ||
Enterprise Value to Revenue 5.4 | Enterprise Value to EBITDA 21.4 | Shares Outstanding 71845400 | Shares Floating 71328077 |
Shares Outstanding 71845400 | Shares Floating 71328077 | ||
Percent Insiders 0.61 | Percent Institutions 97.97 |
Analyst Ratings
Rating 4 | Target Price 278.84 | Buy 2 | Strong Buy 10 |
Buy 2 | Strong Buy 10 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
West Pharmaceutical Services Inc
Company Overview
History and Background
West Pharmaceutical Services, Inc. was founded in 1923. It has evolved from manufacturing rubber closures to providing a comprehensive portfolio of solutions for injectable drug delivery systems and services.
Core Business Areas
- Proprietary Products: Includes stoppers, seals, plungers, and self-injection systems designed for various injectable drug delivery applications.
- Contract-Manufactured Products: Offers contract manufacturing services for pharmaceutical and biotech companies, including device assembly and packaging.
Leadership and Structure
Eric M. Green is the Chief Executive Officer. The company has a board of directors and operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- NovaPure Stoppers: Premium elastomeric stoppers designed to minimize drug interactions. The market for elastomeric stoppers is highly competitive, with market share difficult to pinpoint precisely. Competitors include Datwyler and SCHOTT.
- Self-Injection Systems: Development and manufacturing of self-injection devices for pharmaceutical companies. Competitors include Ypsomed and SHL Medical. Market share data varies depending on specific device categories.
- Daikyo Crystal Zenith: A cyclic olefin polymer (COP) container known for its high purity and compatibility with biologic drugs. Competitors include Schott, Gerresheimer, and Nipro. Market share figures are difficult to obtain due to confidentiality reasons and the evolving market dynamics.
Market Dynamics
Industry Overview
The pharmaceutical packaging and drug delivery market is driven by factors like increasing demand for injectable drugs, biologics, and personalized medicine. It's a regulated market with a focus on quality and safety.
Positioning
West Pharmaceutical Services is a leading provider of innovative solutions for injectable drug delivery. Its competitive advantage lies in its expertise in materials science, manufacturing capabilities, and strong relationships with pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for drug delivery and packaging is estimated to be over $100 billion. West is positioned well to capture a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Strong reputation and brand recognition
- Extensive product portfolio
- Strong customer relationships
- Innovative product development
- Global manufacturing and distribution network
Weaknesses
- Reliance on pharmaceutical industry trends
- Exposure to regulatory changes
- Potential for product recalls
- High capital expenditure requirements
Opportunities
- Expanding into emerging markets
- Developing new drug delivery technologies
- Acquiring complementary businesses
- Increasing demand for biologics and personalized medicine
Threats
- Intense competition
- Pricing pressures
- Economic downturns
- Changes in healthcare regulations
- Patent expirations
Competitors and Market Share
Key Competitors
- DHR
- SYK
- SHC
Competitive Landscape
West Pharmaceutical Services has a strong position in the market due to its expertise and product quality. However, it faces intense competition from other players. Its innovative capabilities and global reach are advantages.
Major Acquisitions
SCHOTT Pharmaceutical Packaging
- Year: 2022
- Acquisition Price (USD millions): 480
- Strategic Rationale: Expanded product portfolio in high value vials and cartridges
Growth Trajectory and Initiatives
Historical Growth: West has experienced steady growth driven by the increasing demand for injectable drugs and its innovative product offerings.
Future Projections: Future growth is expected to be driven by factors like the increasing demand for biologics and personalized medicine. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity and investing in research and development.
Summary
West Pharmaceutical Services is a well-established company with a strong position in the drug delivery and packaging market. It benefits from increasing demand for injectable drugs and biologics. The company faces competition and regulatory risks, but its innovative capabilities and global reach provide a competitive advantage. West's future success depends on its ability to adapt to market changes and capitalize on growth opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Analyst Reports, Industry Publications, Third Party News
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated based on available information and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About West Pharmaceutical Services Inc
Exchange NYSE | Headquaters Exton, PA, United States | ||
IPO Launch date 1978-01-13 | Non-Independent Chair of the Board, President & CEO Mr. Eric M. Green | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 10600 | Website https://www.westpharma.com |
Full time employees 10600 | Website https://www.westpharma.com | ||
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.